Active Ingredient(s): Lixisenatide
FDA Approved: * July 27, 2016
Pharm Company: * SANOFI-AVENTIS US
Category: Diabetes

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Adlyxin Overview

Lixisenatide (trade name Lyxumia in the European Union and Adlyxin in the U.S. and manufactured by Sanofi) is a once-daily injectable GLP-1 receptor agonist for the treatment of type 2 diabetes. Contents 1 Medical use 1.1 Lixisenatide in neurodegenerative diseases 2 Adverse effects 3 Mechanism of action 4 Chemistry 5 History 6 References 7 External links Medical use Lixisenatide is used as adjunct to diet and exercise to treat type 2 diabetes.[1] In the European Unio...

Read more Adlyxin Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source:

Recent Adlyxin Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Solution: 0.05mg/ml, 0.15mg/3ml (0.05mg/ml), 0.1mg/ml, 0.3mg/3ml (0.1mg/ml)
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Adlyxin: (2 results)

Sorted by National Drug Code
  • 0024-5745 Adlyxin Kit by Sanofi-aventis U.S. LLC
  • 0024-5747 Adlyxin 100 ug/ml Subcutaneous Injection, Solution by Sanofi-aventis U.S. LLC

Other drugs which contain Lixisenatide or a similar ingredient: (3 results)